The 3 biomarkers were developed after many years of research at the Blanchette Rockefeller Neuroscience Institute by a team of scientists led by Dr. Daniel Alkon, the Director of the Institute, who previously had spent 30 years conducting research in neuroscience and memory at The U.S. National Institutes of Health (NIH) as a Medical Director in the National Institute of Neurological Disorders and Stroke (NINDS) and as Chief of the Laboratory of Adaptive Systems.

Confirmation of the biomarkers accuracy consisted of double blinded clinical trials conducted at major universities, where age matched controls, non-Alzheimer’s Disease dementia patients and AD patients had skin samples taken and then subjected to the biomarker tests. The biomarker test results were hyper-validated by subsequent brain autopsies of the suspected AD patients, and the use of confirmed non-AD dementia patients in the trials (e.g., Huntington’s Diseases, Parkinson’s or other confirmed forms of dementia), which confirmed that all 3 biomarkers were extremely accurate.

Selection of Diagnostic and Therapeutic Articles